Question explored with the scientific record
Conversation so far
- 1 Do statins reduce strokes?
- 2 What benefits do statins show for people without heart disease (primary prevention)?
- 3 What about ezitimibe for cardiovascular disease and stroke prevention
- 4 What are the main safety risks of ezetimibe+statin (e.g., cancer)?
- 5 What about ezetimibe without statin? Is it an effective therapy?
- 6 How much LDL lowering and heart-risk reduction does ezetimibe monotherapy achieve?
- 7 Is ezetimibe alone effective in lowering apoB?
- 8 What is the best way to lower apoB dramatically without a statin
- 9 What are the side effects and risks of PCSK9 inhibitors vs ezetimibe?
- 10 Do PCSK9 inhibitors or ezetimibe lower apoB more, and how fast?
Answered on this page ↓
Do PCSK9 inhibitors or ezetimibe lower apoB more, and how fast?
PCSK9 inhibitors lower apoB more than ezetimibe, roughly twice as much, and both work within weeks.
The most direct numbers come from separate studies. Ezetimibe 10 mg daily for 4 weeks lowered fasting apoB from 118 to 94.5 mg/dL, about a 20% drop [5]. Injectable PCSK9 inhibitors (evolocumab) lowered LDL‑C by roughly 50–67% in pooled trials, and the authors state that apoB reductions followed similar patterns [3]. A case report on evolocumab plus bempedoic acid showed apoB falling from 129 to 79 mg/dL, about a 39% reduction, though other drugs were involved [1]. A meta‑analysis of oral PCSK9 inhibitors (a different formulation) found an apoB reduction of about 47 mg/dL, but that class is not yet widely used [2].
| Drug | ApoB reduction (approximate) | Time to effect |
|---|---|---|
| Ezetimibe 10 mg daily | ~20% (from 118 to 94.5 mg/dL) [5] | 4 weeks [5] |
| Injectable PCSK9 inhibitor (evolocumab) | ~40–60% (inferred from LDL‑C changes) [3][6] | 8–12 weeks [4][6] |
On speed: ezetimibe showed significant fasting apoB reduction at 4 weeks in a pre‑post study [5]. PCSK9 inhibitors reached maximal LDL‑C lowering by weeks 8–12 in phase 2 and 3 trials [4][6]. Both work in weeks, not days.
The evidence has limits. No head‑to‑head trial directly compared apoB reductions for ezetimibe versus an injectable PCSK9 inhibitor in the same population. The ezetimibe number comes from a small pre‑post study of 20 Japanese men [5]. The PCSK9 numbers are inferred from LDL‑C changes in larger but manufacturer‑funded trials [3][6]. The oral PCSK9 meta‑analysis [2] is for a different drug class.
My call: PCSK9 inhibitors lower apoB more than ezetimibe, by roughly a factor of two, and both reach their effect within a month or two. Confidence: moderate, because no direct head‑to‑head trial with apoB as the primary endpoint exists in this retrieval.
Sources used 6
-
A Call for Use of Lipid Fractionation Studies in Patients With Abnormal Standard Lipid Profiles
A case report demonstrating the use of ion mobility lipid fractionation to guide intensive lipid-lowering therapy in a patient with abnormal standard lipid profiles, showing marked reductions in small dense LDL, ApoB, LDL particle number and LDL-C with PCSK9 inhibition and add-o…
DOI: 10.1210/jcemcr/luaf117 -
Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis
A PRISMA-guided systematic review and meta-analysis finds that oral PCSK9 inhibitors significantly lower LDL-C and related lipid parameters with no major safety concerns versus placebo, based on a limited number of randomized trials, highlighting potential but preliminary clinic…
DOI: 10.1007/s12325-025-03418-x -
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
A post-hoc pooled analysis of multiple evolocumab trials shows substantial LDL-C reduction in patients with mixed hyperlipidemia (elevated triglycerides) that is similar to those without elevated triglycerides, with concurrent improvements in non-HDL-C and ApoB and overall good …
DOI: 10.1007/s10557-016-6666-1 -
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
This study investigates the independent and combined effects of evolocumab and atorvastatin on lipoprotein metabolism in healthy, normolipidemic men, demonstrating that both drugs accelerate the catabolism of apoB-containing lipoproteins, with evolocumab uniquely reducing the pr…
DOI: 10.1161/CIRCULATIONAHA.116.025080 -
The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load
In a pre-post study of 20 overweight/obese Japanese men, four weeks of ezetimibe (10 mg daily) improved postprandial lipid and glucose metabolism after a fat-and-glucose load, reducing triglycerides, apoB-48, LDL-cholesterol, apolipoprotein B, fasting glucose, and postprandial g…
DOI: 10.1016/j.jjcc.2012.07.010 -
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
In statin-treated adults with hypercholesterolaemia, a human monoclonal antibody against PCSK9 (AMG 145) produced dose-dependent, large reductions in LDL-C over 12 weeks with good tolerability in a multicentre randomized trial, supporting PCSK9 inhibition as a new lipid-manageme…
DOI: 10.1016/S0140-6736(12)61770-X